We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/7/2020 10:45 | Alternatively you could just post a valid URL | adobbing | |
26/7/2020 10:38 | hxxps://www-fool-com | beckers2008 | |
25/7/2020 11:34 | Well I sold half at 91.50 but may buy back if it gos much lower. Course it would have been better if I could have sold at 96 but it doesn't pay to be too greedy | mercury123 | |
24/7/2020 17:25 | bunz3, do you not have access to trades? Buy v sell 968k/616k. Nought to do with selling. Go figure. | dudishes | |
24/7/2020 08:19 | DON T KNOW WHY SO MUCH SELLING NOT MAKING SENCE IN MY VIEW ,HAD HOPED FOR MORE OF A MOVE UP NOT ALL THIS SELLING HOPING MANY OF SELLERS NOW MIGHT BE CLEARED | bunz3 | |
23/7/2020 16:06 | surely AZN will get support at 8600 level ! | arja | |
21/7/2020 21:43 | Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days ago and part of our discussion covers AZN. We also chatted about loads of other Stocks and as always a fair bit of general Portfolio Management educational stuff. Anyway, if you use Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want TPI Podcast 27) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, Cheers, WD @wheeliedealer | thewheeliedealer | |
21/7/2020 08:50 | zaxarobai . every 3 months ? are you joking ? | arja | |
20/7/2020 16:20 | It takes years to prove safety. Testing these young fit people is a start. But it is only a start. Covid19 does not bother them too much. Side effects of a powerful vaccine such as this could be worse than the original virus. Long term effects. Stay patient. It sounds like a good start. | careful | |
20/7/2020 16:11 | Think how much AZN can make off a vaccine that we all have to get every three months. | zaxarobal | |
20/7/2020 16:03 | If there is positive news on the vaccine , I'm expecting the share price to double within 6 months | squintyflinty1 | |
20/7/2020 15:11 | Usual buy rumour sell on news nonsense | sundance 13 | |
20/7/2020 15:10 | It seems to be exactly what was leaked last week. | smcni1968 | |
20/7/2020 15:07 | May be the market expected data from the 5000 in Brazil who have been on the trial for the last month.If they had said that, say, 20 on the placebo got covid but none on the vaccine have got it, that would be massive news. | paa65 | |
20/7/2020 14:53 | In conclusion, ChAdOx1 nCoV-19 was safe, tolerated, and immunogenic, while reactogenicity was reduced with paracetamol. A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunisation augmenting neutralising anti- body titres. The preliminary results of this first-in-human clinical trial supported clinical development progression into ongoing phase 2 and 3 trials. Older age groups with comorbidities, health-care workers, and those with higher risk for SARS-CoV-2 exposure are being recruited and assessed for efficacy, safety, and immunogenicity of ChAdOx1 nCoV-19 given as a single-dose or two-dose administration regimen in further trials conducted in the UK and overseas. We will also evaluate the vaccine in children, once sufficient safety data have been accumu- lated in adult studies. Phase 3 trials are now underway in Brazil, South Africa, and the UK and will evaluate vaccine efficacy in diverse populations. | filament | |
20/7/2020 14:51 | was it so bad or maybe not as good as expected ! | arja | |
20/7/2020 14:41 | Report released | smcni1968 | |
20/7/2020 14:31 | For interest | mirandaj | |
20/7/2020 14:18 | Happy with 5% rise whilst we await news. Not very often such a blue chip has that size of daily rise | ayl30 | |
20/7/2020 13:42 | The authors have no control over the publication date or time. | relwood | |
20/7/2020 13:38 | A bit dramatic. the whole world waits for this data. How the scientists love the limelight. we discovered that during the pandemic. | careful |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions